Alivus Life Sciences Ltd ALIVUS
NSE · India · Health Technology
INR 1,380.00+0.70 (+0.05%)
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Global markets are being shaken by rising US Treasury yields, firm Fed hike expectations, expensive crude and a softer rupee, and that mix is hitting Indian equities hard while quietly reshaping the opportunity set. Currency pressure can hurt importers but often helps exporters with foreign-currency revenue. This article walks through three rupee-sensitive Indian exporters exposed to the current news flow, helping you evaluate where risk and potential reward now sit. The stocks highlighted...
Alivus Life Sciences Ltd (BOM:543322) reports robust 36.6% EBITDA margin and 26.5% non-GPL growth, while navigating GPL decline and geopolitical risks.
Alivus Life Sciences Ltd (BOM:543322) reports historic EBITDA margins and robust portfolio expansion, while navigating external pressures and operational setbacks.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.